This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | MicrobiomeTrials
← Back to trials NCT01730833
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer Completed PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2013-07-17Est. Completion: 2021-01-12
Enrollment target: 63 participantsLocations City of Hope Medical Center, Duarte, California, United States City of Hope Antelope Valley, Lancaster, California, United States City of Hope- South Pasadena Cancer Center, South Pasadena, California, United States Other microbiome trials you might be interested in Breast Cancer Locally Advanced Breast Cancer Metastatic Breast Cancer ER Positive Breast Cancer HER2 Negative Breast Carcinoma
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib…
Hot Springs, United States Est. completion Dec 2028
Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Estrogen Receptor-Positive Breast Carcinoma
HER2-Negative Breast Carcinoma
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone thera…
Bloomington, United States Est. completion Jul 31, 2029
Lobular Breast Carcinoma
Lobular Breast cancer staging with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) is not optimal due …
Monaco, Monaco Est. completion Nov 2026